Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 6/20 | 0.35 |
| ▸ | PTK2 | Q05397 | 4/20 | 0.34 |
| ▸ | TRPM8 | Q7Z2W7 | 6/20 | 0.33 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.33 |
| ▸ | EGFR | P00533 | 1/20 | 0.33 |
| ▸ | CNR1 | P21554 | 1/20 | 0.32 |
| ▸ | CNR2 | P34972 | 1/20 | 0.32 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.32 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19640507 | 1.00 | RORC (0.35) | RORCPTK2TRPM8GRIN2BEGFR | |
| SCHEMBL19640436 | 0.92 | PTK2 (0.38) | RORCPTK2EGFR | |
| SCHEMBL19650916 | 0.86 | KCNH2 (0.35) | RORCEGFRCNR1CNR2P2RX3 | |
| SCHEMBL19640597 | 0.86 | RORC (0.40) | RORCTRPM8CNR1CNR2P2RX3 | |
| SCHEMBL19640606 | 0.86 | PTK2 (0.38) | RORCPTK2CNR1CNR2P2RX3 | |
| SCHEMBL29400570 | 0.86 | PTK2 (0.38) | RORCPTK2CNR1CNR2P2RX3 | |
| SCHEMBL29401722 | 0.84 | RORC (0.39) | RORCEGFR | |
| SCHEMBL19640656 | 0.84 | RORC (0.39) | RORCEGFR | |
| SCHEMBL19650918 | 0.83 | EGFR (0.33) | RORCTRPM8EGFRCNR1CNR2 | |
| SCHEMBL19640701 | 0.82 | EGFR (0.33) | RORCTRPM8EGFRCNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11254681-B2 | Optionally fused heterocyclyl-substituted derivatives of pyrimidine useful for the treatment of inflammatory, metabolic, oncologic and autoimmune diseases | NUEVOLUTION A/S (DK) | 2022-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11254681-B2 | Optionally fused heterocyclyl-substituted derivatives of pyrimidine useful for the treatment of inflammatory, metabolic, oncologic and autoimmune diseases | PPARD, PPARG, RORC | RORC 3/4885PTK2 4147/4885TRPM8 2573/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.